Thymopentin improves the survival of septic mice by promoting the production of 15-deoxy-prostaglandin J2 and activating the PPARγ signaling pathway
Autor: | Yong Yang, Wenhao Xie, Ye Zhang, Xianjing Li, Rui Li, Hui Hou, Wenchao Yan, Qian Ye, Qin Di, Xue Yang, Linjun You, Lutz Birnbaumer, Ruifeng Fu, Kun Mo, Yufei Chen, Yanxiang Wang |
---|---|
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Male Inflammation Spleen CITOQUINAS Punctures Pharmacology INFLAMACION Biochemistry Sepsis THYMOPENTIN purl.org/becyt/ford/1 [https] 03 medical and health sciences 0302 clinical medicine Immune system Genetics medicine Macrophage Animals Thymopentin purl.org/becyt/ford/1.6 [https] Molecular Biology Cecum Ligation PPARΓ SEPSIS business.industry 15-D-PGJ2 Prostaglandin D2 TIMOPENTINA medicine.disease Systemic inflammatory response syndrome Mice Inbred C57BL PPAR gamma Survival Rate 030104 developmental biology medicine.anatomical_structure Cytokines medicine.symptom Signal transduction Inflammation Mediators business MACROPHAGE 030217 neurology & neurosurgery Biotechnology medicine.drug Signal Transduction |
Zdroj: | CONICET Digital (CONICET) Consejo Nacional de Investigaciones Científicas y Técnicas instacron:CONICET FASEB Journal. 2020, 34(9) Repositorio Institucional (UCA) Pontificia Universidad Católica Argentina instacron:UCA |
ISSN: | 1530-6860 |
Popis: | Fil: Zhang, Ye. China Pharmaceutical University. State Key Laboratory of Natural Medicines. Center for New Drug Safety Evaluation and Research; China Fil: Yang, Xue. China Pharmaceutical University. State Key Laboratory of Natural Medicines. Center for New Drug Safety Evaluation and Research; China Fil: Yan, Wenchao. China Pharmaceutical University. State Key Laboratory of Natural Medicines. Center for New Drug Safety Evaluation and Research; China Fil: Li, Rui. China Pharmaceutical University. State Key Laboratory of Natural Medicines. Center for New Drug Safety Evaluation and Research; China Fil: Ye, Qian. China Pharmaceutical University. State Key Laboratory of Natural Medicines. Center for New Drug Safety Evaluation and Research; China Fil: You, Linjun. China Pharmaceutical University. State Key Laboratory of Natural Medicines. Center for New Drug Safety Evaluation and Research; China Fil: Xie, Wenhao. China Pharmaceutical University. State Key Laboratory of Natural Medicines. Center for New Drug Safety Evaluation and Research; China Fil: Mo, Kun. China Pharmaceutical University. State Key Laboratory of Natural Medicines. Center for New Drug Safety Evaluation and Research; China Fil: Fu, Ruifeng. China Pharmaceutical University. State Key Laboratory of Natural Medicines. Center for New Drug Safety Evaluation and Research; China Fil: Wang, Yanxiang. China Pharmaceutical University. State Key Laboratory of Natural Medicines. Center for New Drug Safety Evaluation and Research; China Fil: Chen, Yufei. China Pharmaceutical University. State Key Laboratory of Natural Medicines. Center for New Drug Safety Evaluation and Research; China Fil: Yang, Yong. China Pharmaceutical University. State Key Laboratory of Natural Medicines. Center for New Drug Safety Evaluation and Research; China Fil: Birnbaumer, Lutz. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Instituto de Investigaciones Biomédicas; Argentina Fil: Birnbaumer, Lutz. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Di, Qin. Nanjing Sport Institute. School of Sports and Health; China Fil: Li, Xianjing. China Pharmaceutical University. State Key Laboratory of Natural Medicines. Center for New Drug Safety Evaluation and Research; China Abstract: Sepsis, a systemic inflammatory response syndrome (SIRS) caused by infection, is a major public health concern with limited therapeutic options. Infection disturbs the homeostasis of host, resulting in excessive inflammation and immune suppression. This has prompted the clinical use of immunomodulators to balance host response as an alternative therapeutic strategy. Here, we report that Thymopentin (TP5), a synthetic immunomodulator pentapeptide (Arg-Lys-Asp-Val-Tyr) with an excellent safety profile in the clinic, protects mice against cecal ligation and puncture (CLP)-induced sepsis, as shown by improved survival rate, decreased level of pro-inflammatory cytokines and reduced ratios of macrophages and neutrophils in spleen and peritoneum. Regarding mechanism, TP5 changed the characteristics of LPS-stimulated macrophages by increasing the production of 15-deoxy-Δ12,14 -prostaglandin J2 (15-d-PGJ2). In addition, the improved effect of TP5 on survival rates was abolished by the peroxisome proliferator-activated receptor γ (PPARγ) antagonist GW9662. Our results uncover the mechanism of the TP5 protective effects on CLP-induced sepsis and shed light on the development of TP5 as a therapeutic strategy for lethal systemic inflammatory disorders. |
Databáze: | OpenAIRE |
Externí odkaz: |